ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

EVG Evgen Pharma Plc

0.875
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.875 0.85 0.90 0.875 0.875 0.875 116,116 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 422k -4.04M -0.0147 -0.59 2.39M

Evgen Pharma PLC Posting of Annual Report and AGM Notice (1666S)

21/06/2018 12:30pm

UK Regulatory


Evgen Pharma (LSE:EVG)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Evgen Pharma Charts.

TIDMEVG

RNS Number : 1666S

Evgen Pharma PLC

21 June 2018

 
 For immediate release   21 June 2018 
 

Evgen Pharma plc

("Evgen" or "the Company")

Posting of Annual Report and AGM Notice

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that its Annual Report and Accounts for the year ending 31 March 2018 together with the notice of Annual General Meeting ("AGM") have today been posted to shareholders.

The documents are being made available at the investor relations section of the Company's website, www.evgen.com.

The Company's AGM will be held at 2.00pm at the offices of RSM UK Audit LLP, 3 Hardman Street, Manchester M3 7HF on Thursday 26 July 2018.

Enquiries:

 
 Evgen Pharma plc                            c/o +44 (0) 20 7466 5000 
  Dr Stephen Franklin, CEO 
  Richard Moulson, CFO 
  www.evgen.com 
 
 Buchanan 
  Mark Court, Sophie Wills, Tilly Abraham        +44 (0) 20 7466 5000 
 
 Northland Capital Partners Limited 
  Matthew Johnson, Tom Price, Gerry Beaney 
  (Corporate Finance) 
  John Howes, Rob Rees (Corporate Broking)       +44 (0) 20 3861 6625 
 
 

Notes for editors:

About Evgen Pharma plc

Evgen is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company's core technology is Sulforadex(R), a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

Evgen commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.

For further information, please visit: www.evgen.com

For commissioned research on the Company, please visit: http://evgen.com/investors/analyst-coverage/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

ACSFFLFLVQFLBBX

(END) Dow Jones Newswires

June 21, 2018 07:30 ET (11:30 GMT)

1 Year Evgen Pharma Chart

1 Year Evgen Pharma Chart

1 Month Evgen Pharma Chart

1 Month Evgen Pharma Chart

Your Recent History

Delayed Upgrade Clock